Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrier and BRCAness phenotype advanced ovarian cancer patients

Trial Profile

Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrier and BRCAness phenotype advanced ovarian cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Ovarian cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MITO 15
  • Sponsors PharmaMar
  • Most Recent Events

    • 04 Oct 2016 Last checked against European Clinical Trials Database record.
    • 01 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2015 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top